Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top

Tumor Biology

Tumor Markers, Tumor Targeting and Translational Cancer Research

2010 - 2016
Volumes
66
Issues
Chevron right icon
Issue 12/2016
Latest issue

Tumor Biology OnlineFirst articles

Retraction Note to multiple articles in Tumor Biology

Retraction Note

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About this journal

As of Volume 38/2017, Tumor Biology is published by SAGE Publications Ltd. http://tub.sagepub.com

Metadata
Title
Tumor Biology
Coverage
Volume 31/2010 - Volume 37/2016
Electronic ISSN
1423-0380
Print ISSN
1010-4283
Journal ID
13277
DOI
https://doi.org/10.1007/13277.1423-0380
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits